Corrigendum to 'Dynamic profiling in inflammatory Bowel disease: A manifesto for personalized care' [Autoimmunity Reviews 25 (2026) 104068]

The authors regret that the following sentence may be open to misinterpretation. The original sentence read: “However, it is important to note that neither the VIVID nor the GALAXI trials were specifically powered to establish superiority over ustekinumab.” This sentence should be replaced with the following: “It should be noted, however, that neither the VIVID nor the GALAXI trial – investigating mirikizumab and guselkumab, respectively – was specifically designed around the expected head-to-head difference versus ustekinumab, with trial sizing instead based on the expected differences in primary endpoints versus placebo. The head-to-head comparison with ustekinumab was a pre-specified, multiplicity-controlled secondary analysis in both trials; therefore, where superiority over ustekinumab was not demonstrated, it is not possible to distinguish a true absence of superiority from insufficient precision to detect a clinically meaningful difference”. The authors would like to apologise for any inconvenience caused.